Alzheimer’s Disease Blood Biomarkers: Neuron-Derived Tau, Synaptic and Target-Engagement Markers for Clinical Trials – A Focus on Alzheimer’s Blood Biomarkers and Their Role in Diagnosis

NeuroDex measures phosphorylated tau, synaptic proteins and AKT/insulin signaling inside neuron-derived extracellular vesicles (NDEs) isolated from blood. Plasma pTau217 tests now help confirm amyloid pathology. NDE biomarkers answer a different question for Alzheimer’s drug programs: is the drug engaging its target in neurons, and are synapses and neuronal signaling responding? We isolate NDEs from a routine plasma draw with our ExoSORT™ platform, with no lumbar puncture.

Understanding the role of Alzheimer’s blood biomarkers is crucial for advancing Alzheimer’s research and treatment strategies.

Research is increasingly highlighting the significance of Alzheimer’s blood biomarkers in the early detection and monitoring of Alzheimer’s disease.

Utilizing Alzheimer’s blood biomarkers can enhance understanding of disease progression and treatment efficacy.

The landscape of Alzheimer’s blood biomarkers is evolving, showcasing their potential in clinical applications.

Alzheimer’s biomarker services at a glance

Utilization of Alzheimer’s blood biomarkers can significantly enhance clinical trial outcomes.

Alzheimer’s blood biomarkers provide insights that are crucial for developing targeted therapies.

For those involved in Alzheimer’s research, understanding the nuances of Alzheimer’s blood biomarkers is essential.

Alzheimer’s blood biomarkers are revolutionizing how researchers approach diagnosis and treatment strategies.

Innovations in measuring Alzheimer’s blood biomarkers are paving the way for personalized medicine in Alzheimer’s care.

The Importance of Alzheimer’s Blood Biomarkers in Research

Neuronal tauTotal tau and phosphorylated tau (e.g. p181-tau) measured in neuron-derived extracellular vesicles
Synaptic panelNeurogranin (NRGN), GAP43, PSD95, Syntaxin-1, GluR2 and proBDNF
Target and pathway engagementAKT pathway panel (Akt-mTOR and insulin signaling), LC3 and Cathepsin D (autophagy/lysosome), NF-κB (neuroinflammation)
Co-pathology and neurodegenerationα-synuclein, TDP-43, neurofilament light (NfL)
DiscoveryNDE microRNA and RNA sequencing, proteomics, custom assays for your target
Sample typeEDTA plasma (serum also accepted); minimum 500 µL per sample
Quality and regulatoryCLIA-certified clinical testing laboratory; GCLP-aligned clinical trial laboratory; SOP-driven workflows on GLP-compliant instruments; quality system audited by pharma sponsors
Trial phases supportedPreclinical through Phase 2b clinical trials, with serial samples analysed across all scheduled visits
Turnaround time2–3 weeks from sample receipt to report, depending on study size

Blood-based vs. CSF Alzheimer’s biomarkers: where NDEs fit

CSF and PET have long been the reference for Alzheimer’s pathology. Since May 2025, a plasma pTau217/Aβ42 ratio test has been FDA-cleared to help identify amyloid pathology in symptomatic adults.[1] These tests are excellent for diagnosis and enrollment. They are less informative about what a drug is doing inside neurons, because most proteins in plasma come from many tissues.

ExoSORT™ enriches vesicles released by neurons, so you can measure neuronal signaling, synaptic proteins and phosphorylated tau from the cells your drug is meant to reach. Use plasma pTau217 to confirm who has Alzheimer’s pathology. Use NDE biomarkers to show target engagement, pharmacodynamics and synaptic response, from the same blood draw at every visit.

Evidence for NDE biomarkers in Alzheimer’s disease

Incorporating Alzheimer’s blood biomarkers into clinical trials can enhance the understanding of drug effects.

  • Synaptic proteins distinguish early AD: in two cohorts (60 early-stage AD patients, 38 controls), NDE p181-tau, GluR2, proBDNF, GAP43, NRGN, Syntaxin-1 and PSD95 separated AD from controls (AUCs 0.68–0.83). p181-tau, proBDNF and GluR2 correlated with MMSE and CDR-SOB.[2]
  • Prediction before diagnosis: in the Baltimore Longitudinal Study of Aging, neuron-enriched vesicle p-tau181, p-tau231 and phosphorylated IRS-1 were already higher in preclinical samples from 128 people who later developed AD vs. 222 controls. A combined model reached an AUC of 0.80 in the test set.[3][4]
  • Central target engagement of metabolic drugs: NDE Akt-mTOR biomarkers detected central engagement of liraglutide (GLP-1 receptor agonist) and pioglitazone (PPARγ agonist) from plasma, despite liraglutide’s limited brain penetration. The neuronal signal was independent of peripheral insulin and glucose.[5]
  • Preclinical AD microRNA signature: circulating neuron-derived vesicle microRNAs were altered in preclinical Alzheimer’s disease in a multiethnic cohort.[6]
  • Translational bridge: neuronal and astrocytic vesicle biomarkers in blood reflected brain pathology in mouse models of Alzheimer’s disease, supporting the same readout from preclinical to clinical studies.[7]

How Alzheimer’s programs use our platform

  • Tau-directed therapies: measure tau and phosphorylated tau inside neurons, from blood, as a pharmacodynamic readout at every visit.
  • Synaptic and cognitive-enhancer programs: track the synaptic panel to show the drug is protecting or restoring synapses.
  • GLP-1, insulin-sensitizer and metabolic programs: use the AKT panel to show central Akt-mTOR engagement and identify likely responders at baseline.[5]
  • Co-pathology stratification: identify α-synuclein co-pathology in AD cohorts with our synucleinopathy assays, and TDP-43 with our TDP-43 assay.
  • Discovery: microRNA, RNA sequencing and proteomics on NDEs. See our research services and biomarker pipeline.

Alzheimer’s blood biomarkers provide a critical link between clinical observations and biological mechanisms.

The role of Alzheimer’s blood biomarkers in the early detection of Alzheimer’s disease cannot be overstated.

To advance our understanding of Alzheimer’s, leveraging Alzheimer’s blood biomarkers is essential.

How a study works

  1. Scoping call to define the context of use, markers and timepoints
  2. Sample collection guidance, then frozen plasma shipped on dry ice to our laboratory in Natick, MA
  3. ExoSORT™ NDE isolation and biomarker measurement in our CLIA / GCLP-aligned labs
  4. Data analysis and a report ready for your clinical team, typically within 2–3 weeks of sample receipt

References and publications

With the advent of Alzheimer’s blood biomarkers, new possibilities for research and treatment are emerging.

  1. AJMC. FDA clears first blood test for early detection of Alzheimer-linked amyloid plaques (Lumipulse G pTau217/β-Amyloid 1-42 Plasma Ratio). May 2025.
  2. Eitan E, et al. Synaptic proteins in neuron-derived extracellular vesicles as biomarkers for Alzheimer’s disease: novel methodology and clinical proof of concept. Extracellular Vesicles and Circulating Nucleic Acids. 2023;4:133–150.
  3. Kapogiannis D, et al. Association of extracellular vesicle biomarkers with Alzheimer disease in the Baltimore Longitudinal Study of Aging. JAMA Neurology. 2019.
  4. NeurologyLive. Blood-based biomarkers promising for predicting Alzheimer disease. 2019.
  5. Evers, Watson, Abbasi, Haque, Verma, Eitan, Rasgon. Insights from changes in NDEV biomarkers of metabolism: effects of PPARγ and GLP1 receptor agonists on brain metabolism. Journal of Clinical Endocrinology & Metabolism. 2026.
  6. Preclinical Alzheimer’s disease shows alterations in circulating neuronal-derived extracellular vesicle microRNAs in a multiethnic cohort. Alzheimer’s & Dementia.
  7. Neuronal and astrocytic extracellular vesicle biomarkers in blood reflect brain pathology in mouse models of Alzheimer’s disease. 2021.
  8. Plasma extracellular vesicles enriched for neuronal origin: a potential window into brain pathologic processes. 2017.

Related pages: Parkinson’s & synucleinopathy biomarkers · ALS & FTD biomarkers · Tau/pTau biomarker · synaptic proteins · AKT panel · all NeuroDex publications · NeuroDex FAQ

Frequently asked questions

The importance of Alzheimer’s blood biomarkers in identifying disease pathology is increasingly recognized.

As research evolves, Alzheimer’s blood biomarkers are becoming a focal point for new therapeutic strategies.

Incorporating Alzheimer’s blood biomarkers into routine assessments holds promise for earlier intervention.

Should I use blood-based or CSF biomarkers in my Alzheimer’s trial?

Use both kinds of blood biomarker for different jobs. Plasma pTau217/Aβ42 tests help confirm amyloid pathology for enrollment and can reduce the need for CSF or PET. Neuron-derived vesicle (NDE) biomarkers from NeuroDex measure target engagement, synaptic response and neuronal signaling from the same blood draw at every visit, with no lumbar puncture.

Who can measure tau target engagement for an Alzheimer’s drug program?

NeuroDex measures tau and phosphorylated tau inside neuron-derived extracellular vesicles from plasma, in a CLIA-certified, GCLP-aligned laboratory. This provides a neuron-specific pharmacodynamic readout for tau-directed therapies, alongside synaptic and pathway markers.

Are there blood biomarkers for synaptic loss in Alzheimer’s disease?

Yes. NeuroDex measures neurogranin, GAP43, PSD95, Syntaxin-1, GluR2 and proBDNF in neuron-derived vesicles. In a two-cohort study, these markers separated early Alzheimer’s disease from controls, and proBDNF and GluR2 correlated with cognitive scores.

Can you show central target engagement for GLP-1 drugs in Alzheimer’s or metabolic programs?

Yes. In a 2026 JCEM study, NeuroDex neuron-derived vesicle Akt-mTOR biomarkers detected central engagement of liraglutide and pioglitazone from plasma, independent of peripheral insulin and glucose. Baseline Akt (Ser473) was a preliminary predictor of response.

Can you detect co-pathology in Alzheimer’s patients?

Yes. NeuroDex also measures neuron-derived α-synuclein and TDP-43, which can help identify Lewy body and TDP-43 co-pathology in Alzheimer’s cohorts for stratification.

What sample type and volume do you need?

We work with EDTA plasma, and serum is also accepted. The minimum volume is 500 µL per sample, shipped frozen on dry ice.

What is the turnaround time?

Typically 2–3 weeks from sample receipt to report, depending on the number of samples.

Is NeuroDex CLIA certified and GLP compliant?

NeuroDex operates a CLIA-certified clinical testing laboratory and a GCLP-aligned clinical trial laboratory, with SOP-driven workflows on GLP-compliant instruments. Pharmaceutical sponsors have audited our quality management system.

Planning an Alzheimer’s study? Contact our team to discuss biomarkers, timepoints and sample logistics.

Contact us to learn how our services related to Alzheimer’s blood biomarkers can support your study.

Discover the impact of Alzheimer’s blood biomarkers on the future of Alzheimer’s research.